Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research. Each SPECIAL ISSUE – CONGRESS REPORT features informative summaries of key topics from lung cancer to come out of a major international oncology congress.
The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.
Springer is delighted to announce a new memo inOncology SPECIAL ISSUE congress report from this years ASCO!
Congress Report ASCO 2019
Preceptorship Shanghai – Modern Management of Advanced Lung Cancer:
Immunotherapy & Targeted Agents
Springer and the Shanghai Pulmonary Hospital held the Lung Cancer International Preceptorship on the 28th-29th June 2018, in Shanghai, China. The overall topic was the modern management of advanced lung cancer: Immunotherapy & Targeted Agents
Expert interviews at ASCO 2019
Dr. Martin Reck gives an overview on where we are today regarding immunotherpaies in early stage NSCLC, discusses recent insights most relevant with respect to immunotherapies in metastatic NSCLC and new data on SCLC.
Dr Marina Garassino on new insights obtained on the optimal use of PD-L1 expression as a biomarker for immunotherapeutic approaches in lung cancer, the significance of tumor mutational burden and what a future “predictive biomarker algorithm” in lung cancer might look like.
Dr. Rafal Dziadziuszko explains what we can expect from circulation free DNA as a biomarker in the setting of lung cancer diagnosis and treatment and talks about the clinical significance of circulating free DNA in ALK-positive tumors.
Dr. Akito Hata talks about recent insights with regard to the correlation between EGFR mutation status and other biomarkers, the benefit of anti-angiogenic treatment in combination with EGFR-targeted strategies and the ideal treatment sequence with EGFR TKIs.